BreezeMeds Review: It Names Four Pharmacies and Has No Terms of Service

And then there is nothing else

BreezeMeds has no terms of service. `/terms` returns 404. So does `/privacy`, `/pricing` and `/products`.

*(A note on checking that, because it is easy to get wrong: on the apex host those paths return 307, which is just the redirect to www. Follow it and every one is a 404. A check that stops at the 307 concludes the pages exist.)*

A privacy policy does exist — embedded inline on the homepage. Nothing else does.

Now count the words that never appear anywhere on the public site:

| Word | Occurrences | |---|---| | subscription | 0 | | recurring | 0 | | cancel | 0 | | auto-renew | 0 | | refund | 0 |

BreezeMeds sells a medication people take every week for months. It publishes no statement of when you will be charged, how to stop being charged, or whether money can ever come back.

And one more:

| compounded | 0 |

That absence is different in kind. BreezeMeds's own internal product identifiers read `compounded-semaglutide`. The company knows exactly what it is dispensing. The public copy simply never says so — which means a reader is never told the single most important fact about the product: that it is not the approved drug, has no FDA approval, and has never been through a registered trial in the form they will receive.

Two other companies in this same review wave are under open FDA warning letters for blurring precisely that line. BreezeMeds does not blur it. It omits it.

The prices its own code disagrees with

Only two figures are server-rendered on the homepage: "Starting at $199" for weight-loss injections and "Starting at $169" for NAD+. Further product cards hydrate client-side.

Two of those hydrated cards do not match the site's own commerce layer.

Sermorelin is advertised at $100. The code carries $135.

Tirzepatide is advertised "Starting at $399". The code carries $299 as the live price, with $399 as the struck-through old price. The card is quoting the crossed-out number as the starting one.

That second error is unusual and worth dwelling on. Nearly every pricing defect in this review series runs in the seller's favour — a protocol total divided by too many months, an intro rate presented as standing, a starting dose presented as the price. This one runs the other way: BreezeMeds is advertising its tirzepatide as $100 dearer than its own system charges. It is not deceptive. It is a company that is not reading its own website.

Neither figure is filed as a price in this review. A number a company's own commerce layer contradicts is not a price, and picking whichever one is cheaper is exactly how a capture error ships.

Nor can a buyer settle it themselves. No price appears anywhere in the funnel until after eleven clinical screens and a demand for a date of birth. You cannot find out what treatment costs without first handing over your clinical history.

What is actually being sold

BreezeMeds publishes no description of any product. Not for NAD+, not for sermorelin, not for the GLP-1s. There is no mechanism, no indication, no benefit list, no contraindication, no side effect, no storage instruction. Each product is a name, sometimes a price, and a button.

The only quality claim on the site is a phrase in a scrolling banner: "Certified Medication". It names no certification, no standard and no certifying body.

So the evidence has to come from elsewhere.

Injected NAD+, at $169, has no completed randomised human trial supporting a restoration-of-function claim. ¹ The substantial human literature concerns oral precursors — nicotinamide riboside and nicotinamide mononucleotide — different molecules taken a different way.

Sermorelin has no trial at all. A ClinicalTrials.gov search returns no interventional record naming it as the intervention, across six query forms including "sermorelin acetate", "GHRH(1-29)" and "Geref", its withdrawn US brand name, plus a free-text pass. ² The 27 studies returned are other molecules. PubMed holds 24 records mentioning sermorelin and none with a randomised-trial publication type. ³ Controls in the same pass: tirzepatide 158 registry records and 126 papers, tesamorelin 17 and 21, bremelanotide 10 and 11.

Semaglutide and tirzepatide genuinely work, with large phase 3 programmes behind the approved products. ^{4 5}

"The Proven Way to lose 15% of your body weight fast!"

That headline sits on the BreezeMeds homepage, above "Lose 1-2lbs per week."

Proven — the site cites nothing. No trial, no PubMed ID, no study name, anywhere, for any product.

15% — that is STEP 1's figure, about 14.9% from baseline against 2.4% on placebo. It belongs to the approved 2.4 mg semaglutide product. BreezeMeds dispenses a compounded preparation, a word it never uses.

Fast — STEP 1 ran 68 weeks.

1-2lbs per week — no source.

What this means if you are buying

Use the pharmacy list. It is the best thing here: four named facilities with phone numbers, and two doctors you can look up. If you buy, ring the pharmacy and ask for the lot record, because BreezeMeds publishes no certificate of analysis for anything.

Before you buy, understand what you are agreeing to, because the site does not tell you. There is no terms of service. There is no published cancellation policy, no refund policy and no statement of billing interval. Ask, in writing, before you give a card.

Check the price against what you are actually charged. Two of the advertised figures disagree with the company's own system, and the tirzepatide one is $100 too high rather than too low.

And know that the product is compounded — because BreezeMeds will not use the word.